FGFR4 and head and neck cancer: Of note, all but two recommendations for therapies with M3 evidence level, i.e., olaparib for the treatment of a head and neck cancer with FANCL mutation and ponatinib for the treatment of a FGFR4-amplified soft tissue tumor, failed clinical translation.